story of the week
Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients With Chronic Kidney Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients With Diabetic and Non-Diabetic Chronic Kidney Disease: A Prespecified Analysis From the DAPA-CKD Trial
Lancet Diabetes Endocrinol 2021 Jan 01;9(1)22-31, DC Wheeler, BV Stefánsson, N Jongs, GM Chertow, T Greene, FF Hou, JJV McMurray, R Correa-Rotter, P Rossing, RD Toto, CD Sjöström, AM Langkilde, HJL HeerspinkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.